158 related articles for article (PubMed ID: 18490255)
1. Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.
Tariman JD; Love G; McCullagh E; Sandifer S;
Clin J Oncol Nurs; 2008 Jun; 12(3 Suppl):29-36. PubMed ID: 18490255
[TBL] [Abstract][Full Text] [Related]
2. Myelosuppression associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.
Miceli T; Colson K; Gavino M; Lilleby K;
Clin J Oncol Nurs; 2008 Jun; 12(3 Suppl):13-20. PubMed ID: 18490253
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal side effects associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.
Smith LC; Bertolotti P; Curran K; Jenkins B;
Clin J Oncol Nurs; 2008 Jun; 12(3 Suppl):37-52. PubMed ID: 18490256
[TBL] [Abstract][Full Text] [Related]
4. Management of side effects of novel therapies for multiple myeloma: consensus statements developed by the International Myeloma Foundation's Nurse Leadership Board.
Bertolotti P; Bilotti E; Colson K; Curran K; Doss D; Faiman B; Gavino M; Jenkins B; Lilleby K; Love G; Mangan PA; McCullagh E; Miceli T; Miller K; Rogers K; Rome S; Sandifer S; Smith LC; Tariman JD; Westphal J
Clin J Oncol Nurs; 2008 Jun; 12(3 Suppl):9-12. PubMed ID: 18490252
[TBL] [Abstract][Full Text] [Related]
5. Thromboembolic events associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.
Rome S; Doss D; Miller K; Westphal J;
Clin J Oncol Nurs; 2008 Jun; 12(3 Suppl):21-8. PubMed ID: 18490254
[TBL] [Abstract][Full Text] [Related]
6. Steroid-associated side effects in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.
Faiman B; Bilotti E; Mangan PA; Rogers K;
Clin J Oncol Nurs; 2008 Jun; 12(3 Suppl):53-63. PubMed ID: 18490257
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib-induced peripheral neuropathy in patients with multiple myeloma.
Berkowitz A; Walker S
Clin J Oncol Nurs; 2012 Feb; 16(1):86-9. PubMed ID: 22297012
[TBL] [Abstract][Full Text] [Related]
8. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA
J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936
[TBL] [Abstract][Full Text] [Related]
9. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
Richardson PG; Sonneveld P; Schuster MW; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Bladé J; Boccadoro M; Cavenagh JD; Boral AL; Esseltine DL; Wen PY; Amato AA; Anderson KC; San Miguel J
Br J Haematol; 2009 Mar; 144(6):895-903. PubMed ID: 19170677
[TBL] [Abstract][Full Text] [Related]
10. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
11. Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia.
Richardson PG; Laubach JP; Schlossman RL; Mitsiades C; Anderson K
J Natl Compr Canc Netw; 2010 Feb; 8 Suppl 1():S4-S12. PubMed ID: 20141673
[TBL] [Abstract][Full Text] [Related]
12. The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry.
Beijers AJ; Oerlemans S; Mols F; Eurelings M; Minnema MC; Vreugdenhil A; van de Poll-Franse LV
Ann Hematol; 2017 Apr; 96(4):653-663. PubMed ID: 28116479
[TBL] [Abstract][Full Text] [Related]
13. Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.
Kumar SK; Laubach JP; Giove TJ; Quick M; Neuwirth R; Yung G; Rajkumar SV; Richardson PG
Br J Haematol; 2017 Sep; 178(5):756-763. PubMed ID: 28591409
[TBL] [Abstract][Full Text] [Related]
14. Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data.
Maschio M; Zarabla A; Maialetti A; Marchesi F; Giannarelli D; Gumenyuk S; Pisani F; Renzi D; Galiè E; Mengarelli A
Integr Cancer Ther; 2018 Dec; 17(4):1115-1124. PubMed ID: 30295079
[TBL] [Abstract][Full Text] [Related]
15. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
Delforge M; Bladé J; Dimopoulos MA; Facon T; Kropff M; Ludwig H; Palumbo A; Van Damme P; San-Miguel JF; Sonneveld P
Lancet Oncol; 2010 Nov; 11(11):1086-95. PubMed ID: 20932799
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
[TBL] [Abstract][Full Text] [Related]
17. Multiple myeloma: treatment- related peripheral neuropathy.
Dowling M; Kelly M; Meenaghan T
Br J Nurs; 2012 Dec 13-2013 Jan 9; 21(22):1325. PubMed ID: 23249799
[No Abstract] [Full Text] [Related]
18. Management of treatment-related adverse events in patients with multiple myeloma.
Mateos MV
Cancer Treat Rev; 2010 May; 36 Suppl 2():S24-32. PubMed ID: 20472185
[TBL] [Abstract][Full Text] [Related]
19. Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
Koeppen S
Oncol Res Treat; 2014; 37(9):506-13. PubMed ID: 25231692
[TBL] [Abstract][Full Text] [Related]
20. Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array.
García-Sanz R; Corchete LA; Alcoceba M; Chillon MC; Jiménez C; Prieto I; García-Álvarez M; Puig N; Rapado I; Barrio S; Oriol A; Blanchard MJ; de la Rubia J; Martínez R; Lahuerta JJ; González Díaz M; Mateos MV; San Miguel JF; Martínez-López J; Sarasquete ME;
Hematol Oncol; 2017 Dec; 35(4):746-751. PubMed ID: 27605156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
